Skip to main content
Erschienen in: Digestive Diseases and Sciences 3/2019

17.12.2018 | Editorial

Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth

verfasst von: Clara E. Dismuke-Greer, Wing-Kin Syn

Erschienen in: Digestive Diseases and Sciences | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Excerpt

Nonalcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in the USA and in other developed nations, is associated with metabolic risk factors including obesity, type 2 diabetes mellitus (T2DM), dyslipidemia, hypertension, and “non-classical” risk factors such as obstructive sleep apnea and gout [1]. In the USA, the true prevalence of NAFLD is 25–40%, depending on the modalities used to diagnosis NAFLD, and is in parallel with the rising tide of obesity and T2DM [2, 3]. As cardiovascular disease and extrahepatic cancers are the most common causes of death among those with NAFLD [4, 5], NAFLD is now considered a multi-systemic metabolic disease. …
Literatur
1.
Zurück zum Zitat Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006;54:229–239.PubMed Marchesini G, Babini M. Nonalcoholic fatty liver disease and the metabolic syndrome. Minerva Cardioangiol. 2006;54:229–239.PubMed
2.
Zurück zum Zitat Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69:896–904.CrossRefPubMed
4.
Zurück zum Zitat Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–1197.CrossRefPubMed Armstrong MJ, Adams LA, Canbay A, et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59:1174–1197.CrossRefPubMed
5.
Zurück zum Zitat Adams LA, Anstee QM, Tilg H, et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–1153.CrossRefPubMed Adams LA, Anstee QM, Tilg H, et al. Nonalcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66:1138–1153.CrossRefPubMed
6.
Zurück zum Zitat Younossi Z, Stepanova M, Ong JP et al. Global nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2018. https://doi.org/10.1016/j.cgh.2018.0. Younossi Z, Stepanova M, Ong JP et al. Global nonalcoholic Steatohepatitis Council. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2018. https://​doi.​org/​10.​1016/​j.​cgh.​2018.​0.
7.
Zurück zum Zitat Ertle J, Dechêne A, Sowa JP, et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–2443.CrossRefPubMed Ertle J, Dechêne A, Sowa JP, et al. Nonalcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436–2443.CrossRefPubMed
8.
Zurück zum Zitat Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–817.CrossRefPubMed Belli LS, Perricone G, Adam R, et al. Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. J Hepatol. 2018;69:810–817.CrossRefPubMed
9.
Zurück zum Zitat Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed Flemming JA, Kim WR, Brosgart CL, et al. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65:804–812.CrossRefPubMed
10.
Zurück zum Zitat Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.e1.CrossRefPubMed Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015;13:594–601.e1.CrossRefPubMed
11.
Zurück zum Zitat Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.e1.CrossRefPubMed Mittal S, El-Serag HB, Sada YH, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.e1.CrossRefPubMed
13.
Zurück zum Zitat Herzer K, Hofmann TG, Teufel A, et al. IFNalpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69:855–862.CrossRefPubMed Herzer K, Hofmann TG, Teufel A, et al. IFNalpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009;69:855–862.CrossRefPubMed
14.
Zurück zum Zitat Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009;284:26591–26602.CrossRefPubMedPubMedCentral Cazanave SC, Mott JL, Elmi NA, et al. JNK1-dependent PUMA expression contributes to hepatocyte lipoapoptosis. J Biol Chem. 2009;284:26591–26602.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–496.CrossRefPubMed Bettermann K, Vucur M, Haybaeck J, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–496.CrossRefPubMed
16.
Zurück zum Zitat Huang K-W, Leu H-B, Wang Y-J, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15:830–835.CrossRefPubMed Huang K-W, Leu H-B, Wang Y-J, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Dis. 2013;15:830–835.CrossRefPubMed
17.
Zurück zum Zitat Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.CrossRef Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047.CrossRef
18.
Zurück zum Zitat Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.CrossRefPubMedPubMedCentral Musso G, Gambino R, Tabibian JH, et al. Association of nonalcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11:e1001680.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Lee D-H, Jacobs DR, Gross M, et al. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51:1185–1191.CrossRefPubMed Lee D-H, Jacobs DR, Gross M, et al. Serum gamma-glutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2005;51:1185–1191.CrossRefPubMed
20.
Zurück zum Zitat Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–1570.CrossRefPubMedPubMedCentral Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564–1570.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Sung K-C, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98:3637–3643.CrossRefPubMed Sung K-C, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab. 2013;98:3637–3643.CrossRefPubMed
22.
Zurück zum Zitat Cartmell KB, Dismuke CE, Dooley M, et al. Effect of an evidence-based inpatient tobacco dependence treatment service on 1-year postdischarge health care costs. Med Care. 2018;56:883–889.CrossRefPubMedPubMedCentral Cartmell KB, Dismuke CE, Dooley M, et al. Effect of an evidence-based inpatient tobacco dependence treatment service on 1-year postdischarge health care costs. Med Care. 2018;56:883–889.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–260.PubMed Sayiner M, Otgonsuren M, Cable R, et al. Variables associated with inpatient and outpatient resource utilization among medicare beneficiaries with nonalcoholic fatty liver disease with or without cirrhosis. J Clin Gastroenterol. 2017;51:254–260.PubMed
24.
Zurück zum Zitat Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.CrossRefPubMed Younossi ZM, Blissett D, Blissett R, et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016;64:1577–1586.CrossRefPubMed
25.
26.
Zurück zum Zitat Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–1139.CrossRefPubMed
Metadaten
Titel
Coming Complications of Nonalcoholic Fatty Liver Disease: Time to GNASH Your Teeth
verfasst von
Clara E. Dismuke-Greer
Wing-Kin Syn
Publikationsdatum
17.12.2018
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 3/2019
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-018-5426-4

Weitere Artikel der Ausgabe 3/2019

Digestive Diseases and Sciences 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.